Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Iroko Pharmaceuticals, LLC

Latest From Iroko Pharmaceuticals, LLC

Acadia's Nuplazid Expansion Bid Bites The Dust

Nuplazid is a decent earner for the US biotech in psychosis caused by Parkinson’s disease but following previous failures in Alzheimer's and dementia, the drug has now proved a dud for treating the negative symptoms of schizophrenia.

Neurology Clinical Trials

Acadia’s Launch Of Daybue Astonishes Analysts

Not content with a stunning launch in the US, Acadia has splashed out $100m to bag the worldwide rights from partner Neuren for Rett syndrome therapy Daybue.

Neurology Launches

Acadia’s Daybue Gets First Approval In Rett Syndrome

Daybue is the first drug approved to treat the rare neurodevelopmental disorder Rett syndrome, despite high clinical trial incidence of diarrhea. Product labeling includes clinician guidance for the side effect.

Approvals Rare Diseases

With Hopeful Interim Data, Ultragenyx Bets On GeneTx, Angelman Syndrome Candidate

Ultragenyx is buying its Angelman syndrome partner GeneTx for $75m on the heels of an interim Phase I/II readout that shows signs of clinical activity and appears to resolve earlier safety worries.

Rare Diseases Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • iCeutica, Inc.